A Study of Raludotatug Deruxtecan (R-DXd) for Platinum-resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
This study is looking at a new treatment called Raludotatug Deruxtecan (R-DXd) for people with ovarian, primary peritoneal, or fallopian tube cancer that has not responded to platinum-based chemotherapy. R-DXd is an antibody-drug conjugate, meaning it's designed to specifically target cancer cells. The study will compare R-DXd to standard chemotherapy options like Paclitaxel, Topotecan, or PLD. Researchers want to see how safe and effective R-DXd is. To join, you must be at least 18 years old and have a confirmed diagnosis of high-grade serous or endometrioid ovarian cancer, or primary peritoneal or fallopian tube cancer. The main goals are to see how many people respond to the treatment (Objective Response Rate) and how long people live without their cancer getting worse (Progression-free Survival). The study is currently recruiting participants.
- Study design
- This interventional study plans to enroll 860 participants. It has two parts: Part A will determine the best dose of R-DXd, and Part B will compare R-DXd to other chemotherapy options.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your response to treatment will be measured for up to 18 months, and how long you live without your cancer getting worse will be measured for up to 26 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06161025
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Recruiting
PHASE2Ages 18+InterventionalTreatmentDaiichi Sankyo
~860 participants
Updated 2026-07-28 on ClinicalTrials.gov
What's tested:R-DXdPaclitaxelTopotecanPLD
At a glance
Recruiting sites
26 of 164 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment (Part A)
Measured over From date of randomization to data cut off, up to 18 months
+1 more outcome measured
Conditions
Where it's being run
164 sites across 39 statesJapan14
China12
France12
Italy11
Spain11
Texas10
South Korea9
Florida6
Study leadership
- Global Clinical Leader · STUDY_DIRECTOR · Daiichi Sankyo
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Sign and date the informed consent form prior to the start of any study-specific qualification procedures.
Age ≥18 years or the minimum legal adult age (whichever is greater) at the time the informed consent form is signed.
Participants with histologically or cytologically documented high-grade serous ovarian cancer (OVC), high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer.
For Phase 2 (Part A) Participants must have at least 1 lesion, not previously irradiated, amenable to biopsy, and must consent to provide a pretreatment biopsy and on-treatment biopsy tissue sample (on-treatment biopsy sample not required for the Phase 3 part of the study). Fresh pretreatment biopsy may be waived for subjects who consent to provide an archival tumor tissue sample from a lesion not previously irradiated, performed within 6 months of consent and performed after treatment with their most recent cancer therapy regimen.
For Phase 2 (Part A): Has received at least 1 but no more than 3 prior systemic lines of anticancer therapy. For Phase 3 (Part B): Has received at least 1 but no more than 4 prior systemic lines of anticancer therapy:
Neoadjuvant +/-adjuvant considered 1 line of therapy.
Maintenance therapy (eg, bevacizumab, poly-ADP ribose polymerase \[PARP\] inhibitors) will be considered part of the preceding line of therapy.
Therapy changed due to toxicity in the absence of progression will be considered part of the same line.
Hormonal therapy will be counted as a separate line of therapy, unless it was given as maintenance.
At least 1 line of therapy containing bevacizumab, unless the subject is not eligible for treatment with bevacizumab due to precautions/intolerance. Note: Subjects must have progressed radiologically on or after their most recent line of systemic therapy. Biochemical progression will not be considered progression for this study.
Has platinum-resistant disease. If a subject had only 1 line of platinum therapy, must have received at least 4 cycles of platinum, must have had a best response of not PD, and then progressed between \>90 and ≤180 days after the date of the last dose of platinum If a subject had 2 or 4 lines of platinum therapy, must have received at least 2 cycles of platinum and have progressed on or within 180 days after the date of the last dose of platinum.
If mirvetuximab soravtansine (MIRV) is locally available: Has had prior treatment with MIRV for participants with documented high-folate receptor alpha expression, unless the participant is not eligible for treatment with mirvetuximab soravtansine due to precautions/intolerance, or if the treatment is not approved or available locally.
Has at least 1 measurable lesion evaluated by computed tomography or magnetic resonance imaging according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per investigator assessment.
Eastern Cooperative Oncology Group performance status of 0 or 1.
Has adequate organ and bone marrow function as assessed by local laboratory (within 14 days before start of study drug administration).
Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures and study restrictions.
For Phase 3 (Part B) only: Subjects must be eligible for one of the treatments included in the investigator's choice of chemotherapy arm.
Exclusion
Has clear cell, mucinous, or sarcomatous histology, mixed tumors containing any histology, or low-grade/borderline OVC. (Note for Phase 3 \[Part B\]: seromucinous, low-grade serous carcinoma or ovarian sarcoma, carcinosarcoma and undifferentiated carcinoma are excluded.)
Inadequate washout period before Cycle 1 Day 1, defined as follows:
Major surgery \<28 days
Radiation therapy \<28 days (if palliative stereotactic radiation therapy without abdominal radiation, ≤14 days)
Systemic anticancer therapy (including antibody-drug therapy, retinoid therapy, and hormonal therapy) \<28 days or 5 half-lives, whichever is shorter, before starting study drug
Chloroquine/hydroxychloroquine \<14 days
Exposure to another investigational drug within 28 days prior to start of study treatment or current participation in other therapeutic investigational procedures
Clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated or symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Subjects with untreated and asymptomatic brain metastases or subjects with treated brain metastases who are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy, at the investigator's discretion A minimum of 2 weeks must have elapsed between the end of radiotherapy and randomization and there should be no evidence of progression or need for steroid treatment or anticonvulsants for at least 2 weeks prior to randomization. Note: If there is a history or suspicion of central nervous system. Note: If there is a history or suspicion of central nervous system metastasis, a CT scan of the head or MRI of the brain must be performed at baseline.
Any of the following within the past 6 months prior to randomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event.
Uncontrolled or significant cardiovascular disease, including the following:
QT interval corrected with Fridericia's formula interval \>470 ms.
Diagnosed or suspected long QT syndrome.
History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes.
The participant has bradycardia of less than 50 bpm, unless the subject has a pacemaker.
History of second- or third-degree heart block. Candidates with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers.
Myocardial infarction within 6 months prior to screening.
Uncontrolled angina pectoris within 6 months prior to screening.
New York Heart Association Class 3 or 4 congestive heart failure.
Left ventricular ejection fraction \<50% or institutional lower limit of normal as measured by echocardiography or multigated acquisition (MUGA) scan.
Coronary/peripheral artery bypass graft within 6 months prior to screening
Uncontrolled hypertension (HgCTCAE Grade ≥3 hypertension as per NCI-CTCAE version 5.0).
Complete left or right bundle branch block.
Has a history of (noninfectious) ILD/pneumonitis that required corticosteroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease (COPD), restrictive lung disease, pleural effusion, etc) and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc), or prior pneumonectomy.
Chronic steroid treatment (\>10 mg/day), with the exception of the following:
Inhaled steroids for asthma or COPD
Mineralocorticoids (eg, fludrocortisone) for subjects with orthostatic hypotension
Topical steroids for mild skin conditions
Low-dose supplemental corticosteroids for adrenocortical insufficiency
Premedication for treatment groups and/or premedication in case of any hypersensitivity
Intra-articular steroid injections
History of malignancy other than epithelial OVC, primary peritoneal cancer, or fallopian tube cancer within 3 years prior to enrollment, with the exception of those with a negligible risk of metastasis or death (eg, 5-year OS rate \>90%) and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, ductal carcinoma in situ, or Stage 1 uterine cancer).
Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE Version 5.0, Grade ≤1 or baseline. Note: Subjects may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to Grade \>2 for 3 months prior to randomization and managed with SOC treatment) that the investigator deems related to previous anticancer therapy, following discussion with the Sponsor, such as the following:
Chemotherapy-induced neuropathy
Fatigue
Endocrinopathies, which may include hypothyroidism, hyperthyroidism, Type 1 diabetes, hyperglycemia, and adrenal insufficiency
Skin pigmentation (vitiligo)
For Phase 2 (Part A): Prior exposure to other CDH6-targeted agents or an ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, trastuzumab deruxtecan or datopotamab deruxtecan). For Phase 3 (Part B): Prior exposure to other CDH6-targeted agents or an antibody-drug conjugate containing a topoisomerase I inhibitor.
History of hypersensitivity to any excipients in the R-DXd or any known contraindication to treatment with, including hypersensitivity to, the study drug(s).
Has an active or uncontrolled human immunodeficiency virus (HIV) infection.
Has any evidence of severe or uncontrolled systemic diseases (including active bleeding diatheses or active infection, substance abuse) or other factors that, in the investigator's opinion, makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the protocol. Screening for chronic conditions is not required.
Has an active or uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Hepatitis B and Hepatitis C Screening tests are required.
Female who is pregnant or breastfeeding or intends to become pregnant during the study.
Psychological, social, familial, or geographical factors that would prevent regular follow-up.
Prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the subject; alter the absorption, distribution, metabolism, or excretion of the study drug; or confound the assessment of study results.
Has a history of receiving live-attenuated vaccine (messenger RNA \[mRNA\] and replication-deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first exposure to study intervention.
For Phase 3 (Part B) only: Has clinical symptoms or radiographic evidence of intestinal obstruction.
For Phase 3 (Part B) only: Has ascites or pleural effusions that require repeated drainage (less than 4 weeks between drainages).
What this trial measures
- Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment (Part A)From date of randomization to data cut off, up to 18 months
The ORR was defined as the percentage of participants with confirmed Complete Response (CR) or Partial Response (PR), by BICR assessment based on RECIST version 1.1.
- Progression-free Survival (PFS) Based on BICR Assessment (Part B)From date of randomization to data cut off, up to 26 months
PFS is defined as the time from the date of randomization to the date of disease progression, defined as the first documented radiological progression or death due to any cause, whichever comes first.